Autolus Therapeutics GAAP EPS of -$0.18 beats by $0.06, revenue of $20.9M beats by $7.98M
Source: SeekingAlpha
2025-08-12 07:03:25 ET
More on Autolus Therapeutics
- Autolus: A Buy Before Key Data Readout, Potential Expansion Into Autoimmune Market
- Autolus Therapeutics Q2 2025 Earnings Preview
- SA Asks: Which oncology companies are attractive M&A targets?
- Seeking Alpha’s Quant Rating on Autolus Therapeutics
- Historical earnings data for Autolus Therapeutics
Read the full article on Seeking Alpha
For further details see:
Autolus Therapeutics GAAP EPS of -$0.18 beats by $0.06, revenue of $20.9M beats by $7.98M
Autolus Therapeutics plc
NASDAQ: AUTL
AUTL Trading
20.69% G/L:
$1.9009 Last:
3,167,629 Volume:
$1.62 Open:
AUTL Latest News
May 14, 2026 07:00:00 am
Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business UpdatesMay 05, 2026 07:00:00 am
Autolus Therapeutics to Report First Quarter 2026 Financial Results and Host Conference Call on May 14, 2026April 29, 2026 04:05:00 pm
Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost ReductionAUTL Stock Data
$387,238,481
109,839,996
N/A
49
N/A
Biotechnology & Life Sciences
Healthcare
GB
London
